UroGen Pharma Ltd. Investing Cash Flow
UroGen Pharma Ltd. (URGN) reported Investing Cash Flow of -$19.02 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Cash Flow › Investing Activities
us-gaap:NetCashProvidedByUsedInInvestingActivities · last filed 2026-08-05
- UroGen Pharma Ltd. net cash provided by (used in) investing activities for the quarter ending 2026-06-30 was $1.67M, a 94.11% decline year-over-year.
- UroGen Pharma Ltd. net cash provided by (used in) investing activities for the quarter ending 2026-03-31 was -$20.69M.
- UroGen Pharma Ltd. net cash provided by (used in) investing activities for the quarter ending 2025-12-31 was $27.72M, a 54.28% decline year-over-year.
- UroGen Pharma Ltd. net cash provided by (used in) investing activities for the quarter ending 2025-09-30 was $31.40M.
- UroGen Pharma Ltd. net cash provided by (used in) investing activities for fiscal 2025 was $61.56M.
- UroGen Pharma Ltd. net cash provided by (used in) investing activities for fiscal 2024 was -$20.61M.
- UroGen Pharma Ltd. net cash provided by (used in) investing activities for fiscal 2023 was -$953.00K, a 189.91% decline from fiscal 2022.
- UroGen Pharma Ltd. net cash provided by (used in) investing activities for fiscal 2022 was $1.06M, a 73.95% decline from fiscal 2021.
| Period end | Net Cash Provided by (Used in) Investing Activities 3 month | Net Cash Provided by (Used in) Investing Activities 6 month | Net Cash Provided by (Used in) Investing Activities 9 month | Net Cash Provided by (Used in) Investing Activities 12 month | Net Cash Provided by (Used in) Investing Activities 12 month as first filed |
|---|---|---|---|---|---|
| 2026-06-30 | $1.67M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-05 | -$19.02M 10-Q · filed 2026-08-05 | $8.70M derived: sum of 3 quarters · filed 2026-08-05 | $40.10M derived: sum of 4 quarters · filed 2026-08-05 | |
| 2026-03-31 | -$20.69M 10-Q · filed 2026-05-06 | $7.03M derived: sum of 2 quarters · filed 2026-05-06 | $38.43M derived: sum of 3 quarters · filed 2026-05-06 | $66.83M derived: sum of 4 quarters · filed 2026-08-05 | |
| 2025-12-31 | $27.72M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-02 | $59.12M derived: sum of 2 quarters · filed 2026-03-02 | $87.52M derived: sum of 3 quarters · filed 2026-08-05 | $61.56M 10-K · filed 2026-03-02 | |
| 2025-09-30 | $31.40M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | $59.80M derived: sum of 2 quarters · filed 2026-08-05 | $33.84M 10-Q · filed 2025-11-06 | $94.46M derived: sum of 4 quarters · filed 2026-08-05 | |
| 2025-06-30 | $28.41M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-05 | $2.44M 10-Q · filed 2026-08-05 | $63.06M derived: sum of 3 quarters · filed 2026-08-05 | -$43.69M derived: sum of 4 quarters · filed 2026-08-05 | |
| 2025-03-31 | -$25.96M 10-Q · filed 2026-05-06 | $34.66M derived: sum of 2 quarters · filed 2026-05-06 | -$72.09M derived: sum of 3 quarters · filed 2026-05-06 | -$60.09M derived: sum of 4 quarters · filed 2026-05-06 | |
| 2024-12-31 | $60.62M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-02 | -$46.13M derived: sum of 2 quarters · filed 2026-03-02 | -$34.13M derived: sum of 3 quarters · filed 2026-03-02 | -$20.61M 10-K · filed 2026-03-02 | |
| 2024-09-30 | -$106.75M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | -$94.75M derived: sum of 2 quarters · filed 2025-11-06 | -$81.23M 10-Q · filed 2025-11-06 | -$92.58M derived: sum of 4 quarters · filed 2025-11-06 | |
| 2024-06-30 | $12.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-07 | $25.52M 10-Q · filed 2025-08-07 | $14.17M derived: sum of 3 quarters · filed 2025-08-07 | $14.57M derived: sum of 4 quarters · filed 2025-08-07 | |
| 2024-03-31 | $13.52M 10-Q · filed 2025-05-12 | $2.17M derived: sum of 2 quarters · filed 2025-05-12 | $2.58M derived: sum of 3 quarters · filed 2025-05-12 | $6.29M derived: sum of 4 quarters · filed 2025-05-12 | |
| 2023-12-31 | -$11.34M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-10 | -$10.94M derived: sum of 2 quarters · filed 2025-03-10 | -$7.22M derived: sum of 3 quarters · filed 2025-03-10 | -$953.00K 10-K · filed 2025-03-10 | |
| 2023-09-30 | $401.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-06 | $4.12M derived: sum of 2 quarters · filed 2024-11-06 | $10.39M 10-Q · filed 2024-11-06 | $33.50M derived: sum of 4 quarters · filed 2024-11-06 | |
| 2023-06-30 | $3.72M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-13 | $9.99M 10-Q · filed 2024-08-13 | $33.10M derived: sum of 3 quarters · filed 2024-08-13 | -$2.40M derived: sum of 4 quarters · filed 2024-08-13 | |
| 2023-03-31 | $6.27M 10-Q · filed 2024-05-13 | $29.38M derived: sum of 2 quarters · filed 2024-05-13 | -$6.12M derived: sum of 3 quarters · filed 2024-05-13 | -$6.27M derived: sum of 4 quarters · filed 2024-05-13 | |
| 2022-12-31 | $23.11M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-14 | -$12.38M derived: sum of 2 quarters · filed 2024-03-14 | -$12.54M derived: sum of 3 quarters · filed 2024-03-14 | $1.06M 10-K · filed 2024-03-14 | |
| 2022-09-30 | -$35.49M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-14 | -$35.64M derived: sum of 2 quarters · filed 2023-11-14 | -$22.05M 10-Q · filed 2023-11-14 | -$12.92M derived: sum of 4 quarters · filed 2023-11-14 | |
| 2022-06-30 | -$151.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-10 | $13.45M 10-Q · filed 2023-08-10 | $22.57M derived: sum of 3 quarters · filed 2023-08-10 | $33.23M derived: sum of 4 quarters · filed 2023-08-10 | |
| 2022-03-31 | $13.60M 10-Q · filed 2023-05-11 | $22.72M derived: sum of 2 quarters · filed 2023-05-11 | $33.38M derived: sum of 3 quarters · filed 2023-05-11 | $2.64M derived: sum of 4 quarters · filed 2023-05-11 | |
| 2021-12-31 | $9.13M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-24 | $19.79M derived: sum of 2 quarters · filed 2023-03-24 | -$10.96M derived: sum of 3 quarters · filed 2023-03-24 | $4.07M 10-K · filed 2023-03-24 | |
| 2021-09-30 | $10.66M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-10 | -$20.08M derived: sum of 2 quarters · filed 2022-11-10 | -$5.06M 10-Q · filed 2022-11-10 | $44.41M derived: sum of 4 quarters · filed 2022-11-10 | |
| 2021-06-30 | -$30.74M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-11 | -$15.72M 10-Q · filed 2022-08-11 | $33.75M derived: sum of 3 quarters · filed 2022-08-11 | $46.98M derived: sum of 4 quarters · filed 2022-08-11 | |
| 2021-03-31 | $15.02M 10-Q · filed 2022-05-10 | $64.49M derived: sum of 2 quarters · filed 2022-05-10 | $77.72M derived: sum of 3 quarters · filed 2022-05-10 | $95.24M derived: sum of 4 quarters · filed 2022-05-10 | |
| 2020-12-31 | $49.47M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-21 | $62.70M derived: sum of 2 quarters · filed 2022-03-21 | $80.21M derived: sum of 3 quarters · filed 2022-03-21 | $93.24M 10-K · filed 2022-03-21 | |
| 2020-09-30 | $13.23M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-15 | $30.75M derived: sum of 2 quarters · filed 2021-11-15 | $43.77M 10-Q · filed 2021-11-15 | $53.07M derived: sum of 4 quarters · filed 2021-11-15 | |
| 2020-06-30 | $17.51M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-04 | $30.54M 10-Q · filed 2021-08-04 | $39.84M derived: sum of 3 quarters · filed 2021-08-04 | $27.18M derived: sum of 4 quarters · filed 2021-08-04 | |
| 2020-03-31 | $13.03M 10-Q · filed 2021-05-13 | $22.32M derived: sum of 2 quarters · filed 2021-05-13 | $9.66M derived: sum of 3 quarters · filed 2021-05-13 | -$132.52M derived: sum of 4 quarters · filed 2021-05-13 | |
| 2019-12-31 | $9.30M derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-18 | -$3.36M derived: sum of 2 quarters · filed 2021-03-18 | -$145.55M derived: sum of 3 quarters · filed 2021-03-18 | -$145.59M 10-K · filed 2021-03-18 | |
| 2019-09-30 | -$12.66M derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-09 | -$154.84M derived: sum of 2 quarters · filed 2020-11-09 | -$154.89M 10-Q · filed 2020-11-09 | -$154.91M derived: sum of 4 quarters · filed 2020-11-09 | |
| 2019-06-30 | -$142.19M derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-10 | -$142.23M 10-Q · filed 2020-08-10 | -$142.26M derived: sum of 3 quarters · filed 2020-08-10 | -$142.59M derived: sum of 4 quarters · filed 2020-08-10 | |
| 2019-03-31 | -$44.00K 10-Q · filed 2020-05-07 | -$70.00K derived: sum of 2 quarters · filed 2020-05-07 | -$403.00K derived: sum of 3 quarters · filed 2020-05-07 | -$586.00K derived: sum of 4 quarters · filed 2020-05-07 | |
| 2018-12-31 | -$26.00K derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-02 | -$359.00K derived: sum of 2 quarters · filed 2020-03-02 | -$542.00K derived: sum of 3 quarters · filed 2020-03-02 | $35.29M 10-K · filed 2020-03-02 | |
| 2018-09-30 | -$333.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-12 | -$516.00K derived: sum of 2 quarters · filed 2019-11-12 | $35.31M 10-Q · filed 2019-11-12 | -$741.00K derived: sum of 4 quarters · filed 2020-03-02 | |
| 2018-06-30 | -$183.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-09 | $35.65M 10-Q · filed 2019-08-09 | -$408.00K derived: sum of 3 quarters · filed 2020-03-02 | -$528.00K derived: sum of 4 quarters · filed 2020-03-02 | |
| 2018-03-31 | $35.83M 10-Q · filed 2019-05-09 | -$225.00K derived: sum of 2 quarters · filed 2020-03-02 | -$345.00K derived: sum of 3 quarters · filed 2020-03-02 | -$366.00K derived: sum of 4 quarters · filed 2020-03-02 | |
| 2017-12-31 | -$36.05M derived: 10-K 12 month − 6-K 9 month · filed 2020-03-02 | -$36.17M derived: sum of 2 quarters · filed 2020-03-02 | -$36.20M derived: sum of 3 quarters · filed 2020-03-02 | -$36.28M 10-K · filed 2020-03-02 | -$36.38M 20-F · filed 2018-03-15 |
| 2017-09-30 | -$120.00K derived: 6-K 9 month − 6-K 6 month · filed 2018-11-13 | -$141.00K derived: sum of 2 quarters · filed 2018-11-13 | -$223.00K 6-K · filed 2018-11-13 | ||
| 2017-06-30 | -$21.00K derived: 6-K 6 month − 6-K 3 month · filed 2018-08-14 | -$103.00K 6-K · filed 2018-08-14 | |||
| 2017-03-31 | -$82.00K 6-K · filed 2018-05-15 | ||||
| 2016-12-31 | -$719.00K 10-K · filed 2019-02-28 | -$793.00K 20-F · filed 2018-03-15 | |||
| 2015-12-31 | -$301.00K 20-F · filed 2018-03-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Nuvation Bio Inc. (NUVB) | United States | $2.007B | -13.12 |
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |
| PERRIGO Co plc (PRGO) | Ireland | $2.038B | -0.79 |
| Biohaven Ltd. (BHVN) | United States | $1.990B | -3.83 |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| AGIOS PHARMACEUTICALS, INC. (AGIO) | United States | $1.962B | -5.38 |
| Sarepta Therapeutics, Inc. (SRPT) | United States | $1.941B | -13.89 |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| PALVELLA THERAPEUTICS, INC. (PVLA) | United States | $2.105B | -35.55 |
| Braveheart Bio, Inc. (BRVE) | United States | $2.106B |